Litcius/Paper detail

Synthesis of new boron containing compound (CCB-2) based on curcumin structure and its cytotoxic effect against cancer cells

Edy Meiyanto, Ratna Asmah Susidarti, Riris Istighfari Jenie, Rohmad Yudi Utomo, Dhania Novitasari, Febri Wulandari, Mitsunori Kirihata

2020Journal of Applied Pharmaceutical Science15 citationsDOIOpen Access PDF

Abstract

Boron containing compound (BCC) offers the potential further development for therapy against malignant cancers. We successfully synthesized a new compound based on curcumin structure (curcumin analogue) containing boron atoms, namely, CCB-2 and revealed its cytotoxic activities on various cancer cell lines. The compound was simply synthesized based on aldol condensation using acetone and 4-formylphenyl boronic acid resulted a symmetry CCB-2. The compound was then tested for cytotoxic activities in several cell lines. CCB-2 demonstrated cytotoxic effect on MCF-7/HER-2, MCF-7, RAW 264.7, and 4T1 with IC 50 value of 12 M, 54 M, 26 M, and < 10 M, respectively, while less toxic in fibroblast cells. This compound performed superior cytotoxic against highly metastatic cancer cell, 4T1. In addition, CCB-2 induced cells accumulation in G2/M phase, but decreased the accumulation of intracellular Reactive oxygen species level in 4T1 cells. All the data suggest that this new compound is promising to be developed as anti-cancer agent rather than for Boron Neutron Capture Therapy-based cancer therapy.

Topics & Concepts

CurcuminBoronCytotoxic T cellChemistryAnalgesicCombinatorial chemistryStereochemistryPharmacologyOrganic chemistryMedicineIn vitroBiochemistryCurcumin's Biomedical ApplicationsMedicinal Plant ResearchBoron and Carbon Nanomaterials Research
Synthesis of new boron containing compound (CCB-2) based on curcumin structure and its cytotoxic effect against cancer cells | Litcius